Indeed, preliminary analysis of samples from a CC clinical trial (NCT04516616) demonstrated that neoadjuvant chemotherapy (NACT) induced a state transition characterized by increased tumor-infiltrating immune cells, which correlates with response to immune-checkpoint blockade, at least partly through IFN activation. Here, IFNA1 is linked to neoplasm.